What is the recommended treatment protocol for a woman with severe osteoporosis who is not planning pregnancy, including diagnostic workup, calcium and vitamin D supplementation, anabolic therapy, and subsequent anti‑resorptive treatment?

Treatment Protocol for Severe Osteoporosis in Women Not Planning Pregnancy

For a woman with severe osteoporosis not planning pregnancy, initiate treatment with an anabolic agent (teriparatide or abaloparatide) for up to 2 years, followed immediately by antiresorptive therapy (bisphosphonate or denosumab) to maintain bone density gains and prevent fracture. 1, 2

Initial Diagnostic Workup

Before starting treatment, obtain:

• Bone mineral density (BMD) via DXA scan at lumbar spine, total hip, and femoral neck
• Serum calcium, PTH, 25(OH)D levels, and alkaline phosphatase (to rule out Paget disease before anabolic therapy) 2
• Baseline bone turnover markers (BTMs) for monitoring treatment response 2
• Assessment of secondary causes of osteoporosis (thyroid function, celiac screening, hyperparathyroidism)
• Fracture risk assessment using country-specific tools (FRAX or similar) 1

Calcium and Vitamin D Supplementation

Ensure adequate calcium and vitamin D intake throughout all phases of treatment—this is foundational and accompanies all pharmacologic regimens 1, 2. Target serum 25(OH)D levels should be optimized before initiating anabolic therapy.

Phase 1: Anabolic Therapy (First-Line for Severe Osteoporosis)

Severe osteoporosis is defined as: multiple vertebral fractures, very low T-scores (typically ≤-3.0), or advanced age with frailty 2

Medication Selection:

• Teriparatide 20 μg subcutaneously daily OR
• Abaloparatide 80 μg subcutaneously daily 1, 2

Duration: Up to 2 years maximum 1, 2

Rationale:

The 2019 Endocrine Society guidelines specifically recommend anabolic agents as first-line therapy for women at very high fracture risk with severe or multiple vertebral fractures 1. The 2020 AACE guidelines similarly prioritize anabolic agents (abaloparatide, romosozumab, teriparatide) for very high-risk patients 2.

Monitoring During Anabolic Phase:

• BMD assessment every 1-2 years (lumbar spine, hip, femoral neck) 2
• BTMs at 3-6 months to confirm anabolic response (should show significant increases) 2
• Serum calcium if measured should be drawn ≥16 hours after drug administration 2
• Assess for new fractures clinically and with imaging if symptomatic

Important Caveats:

• Do NOT use if patient has Paget disease, open epiphyses, history of skeletal irradiation, unexplained elevated alkaline phosphatase, or increased osteosarcoma risk 2
• Mild transient hypercalcemia may occur but is uncommon 2
• Side effects include nausea, orthostatic hypotension (first few doses), leg cramps 2

Phase 2: Transition to Antiresorptive Therapy (Critical Step)

Immediately after completing anabolic therapy, transition to antiresorptive treatment—this is mandatory to maintain bone density gains. 1, 2

Why This Matters:

The benefits of anabolic therapy are rapidly lost after discontinuation if not followed by antiresorptive therapy. Studies show most anabolic effects wear off within 1 year of stopping without subsequent treatment 1. This transition is non-negotiable.

Antiresorptive Options (in order of preference for severe osteoporosis):

Option 1: Denosumab (Preferred for Severe Cases)

• 60 mg subcutaneously every 6 months 1
• Advantages: Most potent antiresorptive, no drug holiday needed initially, excellent for maintaining anabolic gains
• Critical warning: Never delay or stop denosumab without transitioning to another antiresorptive (bisphosphonate, hormone therapy, or SERM) due to rebound bone loss and vertebral fracture risk 1
• Monitoring: Reassess fracture risk after 5-10 years; continue if high risk persists 1

Option 2: Zoledronic Acid

• 5 mg intravenously annually 2
• Advantages: Once-yearly dosing, strong efficacy, suitable for patients with GI issues
• Duration: Reassess after 3 years; consider drug holiday after 3-6 years depending on fracture risk 2

Option 3: Oral Bisphosphonates

• Alendronate 70 mg weekly OR Risedronate 35 mg weekly
• Advantages: Lower cost, generic available, extensive safety data
• Duration: Reassess after 5 years; consider drug holiday if fracture risk no longer high 2

Ongoing Monitoring and Reassessment

Annual Assessment Should Include:

• BMD monitoring every 1-2 years at same facility with same DXA machine 2
• BTMs to assess compliance and treatment efficacy (target: at or below premenopausal median for antiresorptives) 2
• Clinical fracture assessment (new fractures indicate treatment failure)
• Fracture risk recalculation using updated BMD and clinical factors

Definition of Treatment Response:

• Stable or increasing BMD 2
• No new fractures or vertebral fracture progression 2
• BTMs at or below premenopausal median (for antiresorptives) 2

Drug Holiday Considerations (For Bisphosphonates Only)

If using bisphosphonates after anabolic therapy:

• Oral bisphosphonates: Consider holiday after 5 years if fracture risk no longer high (T-score >-2.5, no new fractures); can continue up to 10 years if very high risk persists 2
• Zoledronic acid: Consider holiday after 3 years for high-risk patients or 6 years for very-high-risk patients 2
• During holiday: Reassess every 2-4 years; resume if BMD declines beyond least significant change (LSC), new fracture occurs, or BTMs rise to pretreatment values 1, 2

Drug holidays are NOT recommended for denosumab—must transition to another antiresorptive if discontinuing 1, 2

Treatment Failure Protocol

If patient experiences bone loss beyond LSC or new fractures despite treatment:

1. Assess compliance first
2. Re-evaluate for secondary osteoporosis causes (malabsorption, hyperparathyroidism, medications)
3. Switch medication class:
   • If on oral bisphosphonate → switch to injectable antiresorptive (denosumab or zoledronic acid)
   • If on injectable antiresorptive → consider romosozumab (if available) or repeat anabolic therapy 2

Alternative Anabolic Option: Romosozumab

Romosozumab (anti-sclerostin antibody) is an alternative first-line anabolic agent for very high-risk patients 2:

• Duration: 1 year only (not 2 years like teriparatide/abaloparatide)
• Must be followed by bisphosphonate or denosumab 2
• Highly effective for rapid BMD gains and fracture prevention 3
• Consider if patient cannot tolerate daily injections

Common Pitfalls to Avoid

1. Starting with bisphosphonates in severe osteoporosis: While bisphosphonates are appropriate for high-risk osteoporosis, severe osteoporosis (multiple vertebral fractures) requires anabolic-first strategy 1, 2

2. Failing to transition from anabolic to antiresorptive therapy: This results in rapid loss of bone density gains 1

3. Stopping denosumab without transition therapy: Causes rebound bone loss and multiple vertebral fractures 1

4. Extending anabolic therapy beyond 2 years: No additional benefit and increases cost without proven safety 2

5. Inadequate calcium/vitamin D supplementation: Undermines all pharmacologic therapy 1

Lifestyle and Fall Prevention

Throughout all treatment phases, implement:

• Resistance and weight-bearing exercise to improve muscle strength and coordination
• Fall risk assessment and prevention strategies (home safety evaluation, vision correction, medication review)
• Smoking cessation and alcohol moderation
• Nutritional optimization (adequate protein, calcium-rich diet)

These non-pharmacologic interventions should accompany all drug regimens 1.